Tipapkinogene sovacivec
Identification
- Generic Name
- Tipapkinogene sovacivec
- DrugBank Accession Number
- DB06239
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Recombinant - Synonyms
- DNA (synthetic vaccinia virus strain MVA human papillomavirus-targeted)
- MVA-HPV-IL2 vaccine
- Tipapkinogene sovacivec
- External IDs
- R-3484
- RG 3484
- RO5217790
- TG 4001
- TG-4001
- TG4001
Pharmacology
- Indication
Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. [Transgene press release]
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P34L5Y2SR5
- CAS number
- 1052105-48-2
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Cervical Intraepithelial Neoplasia (CIN) 1 1, 2 Recruiting Treatment HPV-Related Anal Squamous Cell Carcinoma / HPV-Related Cervical Carcinoma / HPV-Related Vulvar Squamous Cell Carcinoma / Human Papilloma Virus Related Carcinoma / Penile squamous cell carcinoma caused by Human Papilloma Virus (HPV) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at March 19, 2008 16:18 / Updated at June 12, 2020 16:52